Interacciones de Sumatriptán y naproxeno

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Anfetamina, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etiqueta de Anfetamina y dexanfetamina, Advertencias y precauciones)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (etiqueta de Apixabán, Advertencia en recuadro)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Belladona y opio, Interacciones medicamentosas)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Buprenorfina, Interacciones medicamentosas)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Buprenorfina y naloxona, Interacciones medicamentosas)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (etiqueta de Buspirona, Advertencias)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Interacciones medicamentosas)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Butorfanol, Precauciones)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Immediately discontinue concomitant treatment with TONMYA and a serotonergic agent if serotonin syndrome symptoms occur and initiate supportive symptomatic treatment. (etiqueta de Ciclobenzaprina, Advertencias y precauciones)

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (etiqueta de Cidofovir, Interacciones medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Codeína, Interacciones medicamentosas)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (etiqueta de Dabigatrán, Advertencia en recuadro)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (etiqueta de Dexanfetamina, Advertencias)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (etiqueta de Edoxabán, Advertencia en recuadro)

Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (etiqueta de Efavirenz, lamivudina y tenofovir, Advertencias y precauciones)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (etiqueta de Emtricitabina, rilpivirina y tenofovir, Advertencias y precauciones)

…the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (etiqueta de Enoxaparina, Advertencia en recuadro)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Fentanilo, Advertencias y precauciones)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (etiqueta de Fondaparinux, Advertencia en recuadro)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (etiqueta de Granisetrón, Advertencias y precauciones)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona, Interacciones medicamentosas)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona y clorfenamina, Interacciones medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona y homatropina, Interacciones medicamentosas)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Hidrocodona y paracetamol, Precauciones)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidromorfona, Interacciones medicamentosas)

Combinar la hierba de San Juan (hipérico) con antidepresivos y otros fármacos serotoninérgicos aumenta el riesgo de síndrome serotoninérgico. (NCCIH, St. John's Wort)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Levorfanol, Precauciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Lisdexanfetamina, Advertencias y precauciones)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (etiqueta de Litio, Advertencias y precauciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Metadona, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Metanfetamina, Advertencias y precauciones)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etiqueta de Metaxalona, Interacciones medicamentosas)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Methotrexate Clinical Impact: Concomitant administration of some NSAIDs with high-dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (etiqueta de Mirtazapina, Advertencias y precauciones)

MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (etiqueta de Misoprostol, Advertencia en recuadro)

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (etiqueta de Montelukast, Advertencias y precauciones)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Morfina, Interacciones medicamentosas)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Oliceridina, Interacciones medicamentosas)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (etiqueta de Ondansetrón, Advertencias y precauciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etiqueta de Oxicodona, Interacciones medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Oximorfona, Interacciones medicamentosas)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Paracetamol y codeína, Precauciones)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Pentazocina y naloxona, Precauciones)

‎ • Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Petidina (meperidina), Advertencias y precauciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (etiqueta de Pralatrexato, Interacciones medicamentosas)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (etiqueta de Prasugrel, Advertencia en recuadro)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Prometazina y codeína, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Remifentanilo, Advertencias y precauciones)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (etiqueta de Rivaroxabán, Advertencia en recuadro)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Tapentadol, Advertencias y precauciones)

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (etiqueta de Tenofovir, Advertencias y precauciones)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (etiqueta de Trazodona, Advertencias y precauciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (etiqueta de Vortioxetina, Advertencias y precauciones)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Ziprasidona, Advertencias y precauciones)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etiqueta de Sumatriptán y naproxeno, Contraindicaciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etiqueta de Ácido zoledrónico, Interacciones medicamentosas)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (etiqueta de Adefovir, Advertencias y precauciones)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (etiqueta de Afatinib, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (etiqueta de Alendronato, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (etiqueta de Anagrelida, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (etiqueta de Cefotaxima, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Cyclosporine Clinical Impact: Concomitant use of NSAIDs and cyclosporine may increase cyclosporine’s nephrotoxicity. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (etiqueta de Ciprofloxacino, Interacciones medicamentosas)

Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (etiqueta de Citrato de potasio, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (etiqueta de Cloruro de potasio, Interacciones medicamentosas)

…↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (etiqueta de Dapagliflozina, Interacciones medicamentosas)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (etiqueta de Deferasirox, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (etiqueta de Desmopresina, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Digoxin: Concomitant use with sumatriptan and naproxen sodium tablets can increase serum concentration and prolong half-life of digoxin. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (etiqueta de Donepezilo, Advertencias y precauciones)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (etiqueta de Drospirenona y etinilestradiol, Advertencias y precauciones)

Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. (etiqueta de Droxidopa, Interacciones medicamentosas)

Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Advertencias y precauciones)

Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (etiqueta de Emtricitabina y tenofovir, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (etiqueta de Erlotinib, Advertencias y precauciones)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (etiqueta de Febuxostat, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. (etiqueta de Fluconazol, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Naproxen Coadministration (N=18) of naproxen sodium capsules (250 mg) with NEURONTIN (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%. (etiqueta de Gabapentina, Interacciones medicamentosas)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etiqueta de Galantamina, Advertencias y precauciones)

Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (etiqueta de Glibenclamida, Interacciones medicamentosas)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (etiqueta de Glimepirida, Interacciones medicamentosas)

…angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (etiqueta de Glipizida, Interacciones medicamentosas)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (etiqueta de Glipizida y metformina, Precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (etiqueta de Ibandronato, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (etiqueta de Itraconazol, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (etiqueta de Levofloxacino, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (etiqueta de Memantina y donepezilo, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (etiqueta de Mifepristona, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (etiqueta de Moxifloxacino, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (etiqueta de Nalbufina, Interacciones medicamentosas)

Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (etiqueta de Nateglinida, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (etiqueta de Nintedanib, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (etiqueta de Ofloxacino, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (etiqueta de Pentoxifilina, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (etiqueta de Pioglitazona y glimepirida, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (etiqueta de Rivastigmina, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Perform a cardiovascular evaluation in patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan and naproxen sodium tablets. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (etiqueta de Tofacitinib, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Serotonin Syndrome Risk: Potentially life-threatening condition could result from use of Tramadol Hydrochloride Extended-Release Capsules, particularly during concomitant use of serotonergic drugs. (etiqueta de Tramadol, Advertencias y precauciones)

Serotonin Syndrome Risk Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol, including tramadol hydrochloride and acetaminophen, during concomitant use with serotonergic drugs. (etiqueta de Tramadol y paracetamol, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (etiqueta de Voriconazol, Interacciones medicamentosas)

Drugs that Interfere with Hemostasis (e.g. warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking sumatriptan and naproxen sodium tablets with drugs that interfere with hemostasis. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (etiqueta de Fentermina, Advertencias y precauciones)

…angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (etiqueta de Finasterida, Interacciones medicamentosas)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (etiqueta de Glibenclamida y metformina, Interacciones medicamentosas)

In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (etiqueta de Infliximab, Interacciones medicamentosas)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (etiqueta de Lenalidomida, Advertencias y precauciones)

Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (etiqueta de Levotiroxina, Interacciones medicamentosas)

Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (etiqueta de Liotironina, Interacciones medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (etiqueta de Pilocarpina, Interacciones medicamentosas)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (etiqueta de Repaglinida, Interacciones medicamentosas)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etiqueta de Risedronato, Interacciones medicamentosas)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (etiqueta de Tocilizumab, Interacciones medicamentosas)

Drug-drug interaction studies in healthy subjects have been conducted with zileuton immediate-release tablets and digoxin, phenytoin, sulfasalazine, and naproxen. (etiqueta de Zileutón, Interacciones medicamentosas)